Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and other metabolic diseases. We are advancing a proprietary portfolio of extended-duration therapeutic candidates targeting once-monthly and once-quarterly dosing, with the potential to smooth the PK peaks and troughs that can contribute to tolerability issues and to support more consistent, long-term treatment.
Investors 1
Mentions in press and media 1
| Date | Title | Description |
| - | ProLynx | “ProLynx Inc” |
Reviews 0
